Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763744 | 1.00 | CD274 (0.66) | CD274PDCD1 | |
| SCHEMBL26543034 | 0.95 | CD274 (0.61) | CD274PDCD1 | |
| SCHEMBL20763893 | 0.92 | CD274 (0.61) | CD274PDCD1 | |
| SCHEMBL20764129 | 0.90 | CD274 (0.60) | CD274PDCD1 | |
| SCHEMBL20763806 | 0.87 | CD274 (0.63) | CD274PDCD1 | |
| SCHEMBL20764149 | 0.86 | CD274 (0.63) | CD274PDCD1 | |
| SCHEMBL20539841 | 0.84 | CD274 (0.58) | CD274PDCD1 | |
| SCHEMBL23949243 | 0.84 | CD274 (0.58) | CD274PDCD1 | |
| SCHEMBL26543013 | 0.83 | CD274 (0.59) | CD274PDCD1 | |
| SCHEMBL22132101 | 0.82 | CD274 (0.68) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.